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A new inhibitor of human immunodeficiency virus (HIV) has been isolated and purified to homogeneity from the seeds and fruits of the Momordicn 
charuntia. This compound, MAP 30 (Momordica Anti-HIV Protein), is a basic protein of about 30 kDa. It exhibits dose-dependent inhibition 
of cell-free HIV- 1 infection and replication as measured by: (i) quantitative focal syncytium formation on CEM-ss monolayers; (ii) viral core protein 
p24 expression; and (iii) viral-associated reverse transcriptase (RT) activity in HIV-l infected H9 cells. The doses required for 50% inhibition (ID& 
in these assays were 0.83, 0.22 and 0.33 nM, respectively. No cytotoxic or cytostatic effects were found under the assay conditions. These data 
suggest hat MAP 30 may be a useful therapeutic agent in the treatment of HIV-l infections. The sequence of the N-terminal 44 amino acids of 
MAP 30 has been determined. 
Plant protein; Antiviral agent; AIDS 
1. INTRODUCTION 
Momordica charantia (MC) is a medicinal plant in- 
digenous to China. The fruit and seed extracts of MC 
have been used in China for centuries for anti-viral, an- 
titumor and immunopotentiating purposes [ 11. In re- 
cent years, several proteins have been isolated from the 
seed extracts of this plant [2]. These proteins belong to 
the family of single chain ribosome-inactivating pro- 
teins. They inhibit in vitro translation of eukaryotic 
cells by catalytic inactivation of the 60s ribosomal 
subunit. These proteins were also found to inhibit the 
multiplication of herpes simplex virus-l (HSV-1) and of 
poliovirus I in Hep-2 cells [3]. Fruit extracts of MC have 
been shown to possess in vivo antitumor activity and 
immune-enhancement ability. These extracts inhibited 
the formation of prostate adenocarcinoma in rats [4] 
and lymphoma in mice [5]. 
In view of these findings, we were particularly in- 
terested to study the effects of MC extracts on human 
immunodeficiency virus type-l (HIV-l), the etiologic 
agent of acquired immunodeficiency syndrome (AIDS). 
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In this manuscript, we report the isolation and 
purification to homogeneity of an anti-HIV protein, 
MAP 30, from the seeds and fruits of MC. We also 
report the characterization of the anti-HIV activities 
and the amino terminal sequence of this plant protein. 
2. MATERIALS AND METHODS 
2.1. Momordica charantia plant 
There are many varieties of MC. The content of MAP 30 is most 
abundant in the medicinal variety, which has not been naturally 
available in this country. Cultivation has thus been carried out from 
selected seeds. 
2.2. Cell lines and viruses 
The CDCpositive T cell line CEM-ss (syncytium-sensitive L u 3a- 
positive) was used as indicator cell for the microtiter syncytial- 
forming assay [6]. The H9 cell line was used for p24 expression and 
viral-RT activity assays. HIV-l virus stock was obtained from R. 
Gallo. The virus was prepared and stocked as described previously 
[7]. The cell lines were maintained in RPMI-1640 with penicillin- 
streptomycin (100 U/ml) and 10% heat-inactivated fetal calf serum 
(complete medium). 
2.3. Purification and characterization of MAP 30 
For a routine preparation, 200 g of matured seeds were used. Brief- 
ly, the seeds were decorticated and pulverized. It was then extracted 
with ice-cold 0.15 M NaCl (solution A) by homogenizing for 5 min at 
a ratio of 6 ml of solution A per gram of seeds. The pH of the extract 
was adjusted to 3.6 with 1 M HCI. The mixture was stirred gently at 
4°C for 15 min. Cell debris were removed by filtration with 
cheesecloth, followed by centrifugation at 12 000 xg for 30 min. The 
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cleared supernatant was fractionated by precipitation with am- 
monium sulfate or chilled acetone f-20*C}. The fraction in the 
3060% safurated ammonium sulfate or two volumes of acetone was 
frzund to eontin ant&WIV a&&y, The precipitate was dissolved in 
SO mM sodium ghospfrate, pH 6.3 (solution Bj and dialyzed a8&nst 
the same soiution. This material was referred to as Step I sample and 
was further purified by chromatography on CM-Sepharose CL 6B 
(CM-S) and Sephadex 075 superfine (Pharmacia-LKB). For the 
preparations of MAP 30 from ripe fruits, 2-5 kg were used routinely. 
Fresh indicator c&Is in complete medium were plated onto poIy(L- 
lysinej-coated microtiter wells at 50 000 cells in 50 gl/weil. The ceils 
were pre-treated with 50 gl of MAP 30 at various concentrations 
(Table I), for 15 s or 90 min. At the end of these times, 50 d of a 
frozen pre-titered HIV stock from H x B3/H9 cells, corresponding to 
one hundred syncytial formin units (SW) was added to each well for 
68 min. The supernatant contra MAP 30 and the virus was then 
removed from each well and the cells were washed with complete 
medium to remove residual free MAP 30 and HIV. The wella were 
then filled with 200 rl medium (15 s or 80 min preincubation) or refed 
medium containing MAP 30 at the same original concentration (con- 
tinuous presence of MAP 30 for 120 h). The plates were incubated at 
37°C in a humidified incubator at 5% COz. Pocal syncytium forma- 
tion rep~sen~~ a single infectious virion unit was scored at day 5 by 
~x~~~~~~ un&er an inverted microscope. 
2.5 p24 expression and mverse transcrip&se assays 
The effect of MAP 30 on HIV-1 replicatlon and transmission in 
vitro was tested by viral core protein p24 expression [7] and viral-RT 
activity [Sl. H9celfs were inoculatea with a titered cryopreserved viral 
stock of HWHTLV-IIIB at a multiplicity of infection of 0.005, Cells 
were incubated at 5 x lQ’!ml with the inane at 37°C for 60 n&n to 
allow viral absorption. The cells were t&n v.ashed to remove un- 
bound virus, and resuspended in complete medium. They were plated 
at 1 X Id/ml with or without the addition of MAP 30 for the duration 
of the experiment. In this assay, at the multiplicity of infection used, 
viral production peaks at day 4. Thus, p24 expression and HIV- 
associated RT activity were assayed in cell-free supernatants 
harvested at day 4. 
Cytotoxicity of MAP 30 was measured by its effects on cellular syn- 
thesis of DNA and protein. The synthesis of these macromolecules 
was measured by pulse labeling the cells with 1 $i of [“Hlthymidine 
or [3H]leucine 8 h prior to harvesting at day 4. The incorporation of 
labeled precursor into ~-i~oluble products was measured by scin- 
tlll~t~on counting. Cell viability was determined by Trypan blue dye 
exclusion. 
2.7. &quence analys;lc 
Thor N-terminal amino acid sequence of MAP 30 was determined by 
automated Edman degradation using an Applied Biosystems model 
47OA protein sequencer, with on-line PTH analyzer. 
In vitro translation of evkaryotic cells was measured by the inco~- 
poration of 3H-labeled leucine into TCA-insoluble product in a rabbit 
reticulocyte lysate system [9] (Du Pont-New England Nuclear). The 
reaction was carried out at 37’C for 30 min in a total volume of 25 
~1. The reaction mixture contained I gg of globin mRN.4, 2 mM 
M~Acz, 80 mM KAc, ~~sla~on cock&II (2.5 mM spermidine, 34.5 
mgiml creatine phosphate, 25 m&ml GTP in 250 mM HEPES buf- 
fer) and I @i of fH]leucine. 
3. RESULTS 
3.11 ~~~~~~~~~o~ of M mordica charantia 
Seeds were planted and geminate after I4 to 20 
days. Plants began to bear fruit af%er 60 to 8Q days and 
the fruit matured to ripeness by 90 to 120 days. Extracts 
were prepared from various parts of the plant at dif- 
ferent stages of maturation for the isol~tiun~ purifica- 
tion and id~ti~~~ion of antitumor and anti-HIV corn- 
ponents, In the course of our work, it became evident 
that a potent anti-HIV component was present in the 
fruit and seed, and that its content increased 
significantly with the maturity of the fruit and seed. 
Fig* IA shows 8 growing Mf: fruit which is green in col- 
or, As t.he fruit matured, its color turned to light yellow 
and fintllly bright orange as it reached full maturity. If 
the fruits were not harvested at this stage, they split 
open spontaneously, exposing the matured red seeds as 
seen in Fii. 1B. Only naturally ripened fruits and seeds 
were s&xteb far the prep~ation of h%AP 30. 
3.2. Pwification and characterization of MAP 30 
Step 1 sample (153 rn8) was loaded onto a column 
(1.5 x 34 cm) of CM-S equilibrated with solution B. The 
column was washed with the same solution to remove 
unboxed ~purities~ Whereas &ZAP 30 bound to CM-S 
and was thus retained on the column Fractions of 6 ml 
were collected at a flow rate of 36 ml/h. The elution was 
monitored by absorbance at 280 nm (A&. Upon 
reaching the baseline absorbance, the column was then 
eluted with a linear gradient consisting of 240 ml of 
sulution B and 240 ml of solution I3 ~n~~~ 0.2 
M NaCl. A typica3 &&ion profile is shown in Fig. 2 and 
five protein peaks were eluted. Fractions in each peak 
were assayed for anti-HIV activity, inhibition in 
translation and cytotoxicity. MAP 30 was found in 
peak 2, which was eluted between 60 to 70 mM NaCl, 
This rn&erial was designated as step 2 sample (14.5 mg), 
It was further purified by gel filtration on a column 
(1.5 x 134 cm) of Sephadex G75 in 20 mM sodium 
phosphate buffer, pH 6.3. The flow rate was at 3 ml/h 
and 1.5 ml fractions were collected, Homogeneous 
MAP 30 was eluted as a single peak at about 0.45 col- 
umn volume. 
The size, homogeneity and subunit structure of MAP 
30 were determined by SDS-PAGE in the presence and 
absence of 2-mercaptoethanol. These results are shown 
in Fig” 3. A single band with a molecular mass cor- 
res~~d~~~ to 30 kDa was ubtained for MAP 30 both in 
the p~@ence ar$ absence of the reducing agent, in- 
dicating that this protein consists of a single chain 
polypeptide. 
This assay quanti~t~ acute cell-free HIV-I infection 
and is bafed on the i~te~action between fusigenie virus- 
infected cells expressing the HIV envelope gene prod- 
ucts and uninfected adjacent cells bearing CD4 
molecules. The results of two independent experiments 
are summarized in Table I and Fig. 4. A 96 min pre+ 
ineub~~on of the indicator cells with MAP 30 resulted 
in dose-dependent i~~bition of HIV infection. At f .67 
13 
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Fig. I. (A) Photograph of a MC plant with an immature fruit in its characteristic green color. (B) A ripened fruit with bright orange outer skin 
and red seed. 
14 
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Fig. 2. Purification of MAP 30 by CM-Sepharose CL6B. Step 1 sam- 
ple (153 mg) was chromatographed on a column of CM-S (1.5 x 34 
cm) as described in the text. Absorbance at 280 nm (-), NaCl 
molar concentration (- -). Fractions of MAP 30 were pooled as 
marked in peak 2. 
and 1670 nM, MAP 30 caused 60% and 86% inhibition 
on syncytium formation, respectively. An IDso of 0.83 
nM was obtained from these results. At the same con- 
centrations, a 15 s pre-treatment caused 23% and 25% 
of inhibition, respectively. Under none of these condi- 
tions was any cytotoxic or cytostatic effect to the in- 
dicator cells observed. Continued presence of MAP 30 
1 2 3 4 5 6 7 8 9 10 
KD 
Fig. 3. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) of 
MAP 30 in the presence of absence of 2-mercaptoethanol. Elec- 
trophoresis was carried out at a constant voltage of 80 V for 6 h. 
Lanes l-5, samples treated with 2-mercaptoethanol: lane 1, molecular 
weight standards, 2 pg each; lane 2, crude MAP 30, 100 pg (30-60% 
saturated ammonium sulfate); lane 3, crude MAP 30, 100 fig (2.0 vols 
acetone); 4 and 5, homogeneous MAP 30, 8 fig each lane, purified 
from lanes 2 and 3, respectively. Lanes 6-10 are the same correspon- 
ding samples as in lanes 1 to 5, but without 2-mercaptoethanol treat- 
ment. 
in the HIV infected cell culture for 120 h produced a 
higher inhibitory effect at all of the concentrations 
tested, with complete elimination of syncytium forma- 
tion at 167 nM (legend of Table I). These results suggest 
that MAP 30 affects initial HIV infection as well as 
transmission of viral gene products through cell contact 
or release of free virions. 
3.4. Inhibition of viral core protein p24 expression 
To assess the antiviral activity of MAP 30 on another 
human T cell line in a suspension culture, p24 expres- 
sion and viral-RT activity were examined in HIV- 
infected H9 cells. The expression of p24 was measured 
by RIA and expressed in ng/ml. As seen in Table II, in 
the presence of 0.334 nM MAP 30, the expression of 
~24 was reduced to 29% of the untreated control. As 
the concentration of MAP 30 was increased, inhibition 
of ~24 expression also increased. Virtually complete in- 
hibition was observed at 33.4 nM. The IDSO was about 
0.22 nM. The reduced production of ~24 was not due to 
cytotoxic or cytostatic effects, and no decrease in 
cellular DNA or protein synthesis was observed at these 
MAP 30 concentrations. 
3.5. Inhibition of viral associated R T activity 
RT activity was measured using poly(rA). p(dT)lz_rs 
as template-primer and 3H-labeled dTTP as substrate. 
The results are expressed as the polynucleotide incor- 
poration of ‘H label in terms of cpm/ml (Table II). 
HIV-RT activity was reduced to 52, 25, 13 and 6% of 
control activity, in cells treated with 0.334, 3.34, 33.4 
and 334 nM of MAP 30, respectively. The IDSO for this 
assay was about 0.33 nM. The reduction in HIV-RT ac- 
tivity is likely to be due to a decrease in virion produc- 
tion, which is also evidenced by decreased ~24 expres- 
sion. 
3.6. Assays on cytotoxicity 
In order to ascertain that the anti-HIV activity of 
MAP 30 is virus specific, the effect of MAP 30 on 
cellular DNA or protein synthesis was determined in 
uninfected H9 cells. These results are shown in Table II. 
From 0.334 to 33.4 nM, MAP 30 caused no detectable 
effect on cellular incorporation of labeled thymidine or 
leucine, while the majority of ~24 and HIV-RT produc- 
tions were inhibited. Even at 334 nM (in the range of 
lo3 x ID~o), MAP 30 only yielded 25% or 28% reduc- 
tions in cellular DNA or protein synthesis, respectively, 
as compared to virtually total inhibition of ~24 and 
HIV-RT production in HIV-infected H9 cells. A 
therapeutic index of at least 1000 was observed. 
3.7. N-Terminal sequence of MAP 30 
The sequence of the first 44 amino acids from the N- 
terminus of MAP 30 is shown in Table III. A search in 
the EMBL protein databank and a structural analysis of 
MAP 30 sequence reveal homology with the N-terminal 
15 
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Table I 
The effect of MAP 30 on HIV infection as measured by syncytium formation in infectious cell center assay of HIV-infected CEM-SS cells 
MAP 30 Syncytia/well in ICC % ICC (V”/ V,) Cytotoxicity 
nM (fig/ml) preincubation preincubation preincubation 
15 s 90 min 15 s 90 min 15 s 90 min 
0* 94 94 100 100 
1.67 (0.05) 71,74 35,41 77 40 
16.7 (0.5) 63,75 31,23 73 29 
167 (5.0) 70,74 18,21 71 21 
1670 (50) 62,71 16,lO 71 14 
Each test point was carried out in duplicate. Duplicate wells of indicator cells containing MAP 30 at each concentration without virus exposure 
were also included for the determination of MAP 30 cytotoxicity. % ICC (infectious cell center) are expressed in terms of V,J V, (average number 
of syncytia in MAP 30 treated samples/average number of syncytia in untreated controls); the values are the averages of two independent ex- 
periments. These experiments were carried out by preincubation of the indicator cells with MAP 30 for the specified time prior to the addition 
of virus. MAP 30 and virus were then removed by washing with complete medium and the cells were incubated with medium alone. In the untreated 
control experiment (*), the number of SF/ICC per well is the averaged value of 101, 92, 96 and 87. In the continuous presence of MAP 30 for 
5 days, the WV. values are 39, 21, 0 and 0 for 1.67, 16.7, 167 and 1670 nM of MAP 30, respectively. 
amino acid sequences of ricin A chain and trichosanthin 
[ 10,111. The sequences of ricin A and trichosanthin are 
shown underneath the sequence of MAP 30 in Table 
III. It is interesting to note that most aromatic and 
hydrophobic amino acids in the predicted B sheet 
region are identical between these proteins. 
3.8. Inhibition of in vitro translation of eukaryotic cells 
The effect of MAP 30 on in vitro translation of 
eukaryotic cells is shown in Fig. 5. The results are ex- 
[MAP301 nM M 1.67 
I I 16.7 
N 167 
W 1670 
15” 90’ 
Time Of Preincubation 
Fig. 4. The effect of MAP 30 on HIV infectivity as measured by syn- 
cytium forming unit (SFU) in the infectious cell center (ICC) assay. 
The results of syncytium per well are expressed in terms of % control. 
Experimental conditions were described in the legend of Table I. 
Uncertainties are indicated by error bars. 
pressed in terms of [3H]leucine incorporation into 
TCA-insoluble product. MAP 30 exhibited a dose- 
dependent inhibition of cell-free translation with an 
IDso of 3.3 nM. 
4. DISCUSSION 
In this paper, we have reported the isolation, 
purification and characterization of an anti-HIV pro- 
tein, MAP 30, from MC. Our results indicate that MAP 
30 mediates potent yet specific interventions of the life 
cycle of HIV-l. The inhibition of syncytium formation 
in acutely infected CDCpositive indicator cells suggests 
that MAP 30 affects initial HIV infection and transmis- 
sion of viral gene products through cell contact or 
release of free virions. The inhibition of p24 expression 
and viral-RT activity indicates that MAP 30 affects 
virion production and replication. Focal syncytium for- 
mation represents ingle infectious virion units. When 
MAP 30 is present only during the initial exposure to 
virus, i.e. 15 s or 90 min preincubation, this assay is 
specific for the initial phase of viral infection. Inhibi- 
tion of syncytia formation by itself should result in 
some decrease in p24 expression and viral associated RT 
activity when these events are measured in the same 
assays. In separate studies, we have indeed observed 
these effects. The effect of MAP 30 on replicative 
events after internalization of the virus into the target 
cell can be specifically measured independent of the in- 
fection phase. In the in vitro p24 expression and RT ac- 
tivity assays, MAP 30 was added to the infected culture 
after the initial viral infection. Inhibition of these 
events may or may not be related to the inhibition on 
syncytia formation. Further studies are needed to 
define the molecular mechanism of the anti-HIV activi- 
ty of MAP 30. 
The N-terminal 44 amino acid sequence of MAP 30 
has been determined. This information represents the 
first protein sequence data from the plant MC. Com- 
16 
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Table II 
T’le effect of MAP 30 on HIV replication as measured by p24 expression and viral-RT activity in HIV-infected H9 cells 
MAP 30 p24 Expression RT activity Qo Cellular, [3H]- 
nM @g/r 11) ng/ml Qo control cpm x lO’/ml Qo control thymidine leucine 
0 2106 100 806 100 100 100 
0.334 ,O.Ol) 610 29 422 52 102 101 
3.34 (0.1) 189 9 202 25 99 102 
33.dO (1.0) 42 2 108 13 101 98 
334.L (10) 0 0 52 6 75 72 
The amount of p24 viral antigen produced was measured by RIA and expressed in ng/ml. Viral-RT activity was assayed by the incorporation of 
[‘H]dTTP into acid-insoluble products and expressed in terms of cpm x lO’/ml. Cytotoxicity was measured by cellular uptake of [‘Hlthymidine 
or [‘H]leucine into TCA-precipitable products in pulse labeling experiments as described in Methods. Results are normalized to values obtained 
for control cultures without MAP 30. Control cpm for [‘Hlthymidine was 206 217, for [3H]leucine was 62 439. Values shown are averages of 
duplicates in two independent experiments. Uncertainties are within 6%. 
Table III 
N-terminal amino acid sequence of MAP 30 and its comparison with trichosanthin and ricin A chain 
MAP 30 
Tri 1 
Ric A Ala- Gly - 
MAP 30 
Tri 1 
Ric A 
MAP 30 
Tri 1 
Ric A 
MAP 30 
Tri 1 
Ric A 
11 
Ala 
Ser 
Val 
f 
21 
Phe - Arg - 
Leu - 
Ll 
Arg - 
val- Ar - 
Phe - 
Phe - 
Ile - 
Be - 
1 Phe - Ile - 1 
Phe- Ser- 
Asn - Glu - 
Thr - Gly - 
31 
Val- 
Leu - 
Val - 
Tyr - Asp - Ile - Pro- Leu- Leu- Tyr - 
Arg - 
Arg- 
MAP 30 
Tri 1 
Ric A 
41 44 
IIe - 
q 
Ser - Asp - Pro - 
Leu - Pro - Gly - Ser - 
Leu - Pro - Ile - Asn - 
20 
Glu - Asp - 
Ser - Asn - 
Arg- Ala - 
30 
His - 
Arg- 
Ala- Asp - 
Leu - Pro - 
Comparison of the N-terminal 44 residues of MAP 30 to the N-terminal sequences of trichosanthin (Tri 1) and ricin A chain (Ric A) residues 7-51 
as reported earlier [lo]. Boxed regions are identical or conserved amino acids of these plant proteins. Substitutions of amino acid with similar 
physio-chemical properties of the side chains are taken as conservative as with Ser and Thr; Val, Leu and Be; Asp and Glu. 
parison of this sequence to the EMBL data bank reveals 
34% or 25% homology to ricin A chain and 57% or 
43% homology to trichosanthin when conserved or 
identical residues are considered. Like ricin and 
trichosanthin, MAP 30 also inhibits in vitro translation 
of eukaryotic cells. Distinct from these compounds, lit- 
tle cytotoxicity has been observed for MAP 30. 
Trichosanthin is a 26 kDa protein isolated from the 
root tuber of Trichosanthes [12,13]. This protein has 
been used for inducing abortions and for treating 
trophoblastic tumors [14-161. It has also been shown to 
inhibit protein synthesis in vitro [17]. Recently, 
trichosanthin was reported to have anti-HIV activity 
and re-named GLQ 223 [ 181. It is important o note that 
under identical assay conditions, MAP 30 is much less 
cytotoxic as compared to GLQ 223. For example, at 
IDgo (inhibitory dose at 90% inhibition) for HIV-RT 
activity, GLQ 223 caused about 35% and 40% inhibi- 
tion on cellular synthesis of DNA and protein, respec- 
tively ([ 181 and our unpublished observations), whereas 
at the same inhibitory dose, MAP 30 showed no detec- 
table inhibition on the synthesis of these 
macromolecules (Table II). Even at 10 x IDgo, MAP 30 
caused only about 25% and 28% inhibition on cellular 
incorporation of ‘H-labeled thymidine and leucine, 
respectively. MAP 30 is thus at least one order of 
magnitude lower in cytotoxicity than GLQ 223. The 
lower in vitro cytotoxicity of MAP 30 suggests that it 
may have a much better therapeutic index. 
The isolation of several bioactive proteins from MC 
has been reported [2-51. Some of these proteins are ac- 
tive in ribosome inactivation while others have been 
17 
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Fig. 5. Effect of MAP 30 on the in vitro translation i a reticulocyte 
lysate system. The extent of protein biosynthesis was measured by the 
incorporation of [3H]leucine (cpm x 104/td) into TCA-insoluble pro- 
duct as a function of MAP 30 concentration. 
reported to be active in inhibiting the development of
tumors in animals [4,5] as well as the multiplication f 
viruses in Hep-2 cells [3]. These proteins are known as 
MC inhibitors (23-24 kDa) and Momorcharins alpha 
and beta (32 and 28 kDa). No amino acid sequence data 
have been reported on these proteins; thus, no com- 
parison can be made with our sequence data on MAP 
30. 
Our results demonstrate hat MAP 30 inhibits both 
infection and replication of HIV-1. Treatment of HIV- 
infected individuals with MAP 30 may block further 
depletions of CD4-T cells and inhibit viral replication. 
Such effects may be important in maintaining latency 
for asymptomatic patients. MAP 30 may prove to be 
synergistic in conjunction with other drugs such as 
AZT. The question of how effective MAP 30 is, alone 
or in combination with other anti-HIV drugs, in the 
treatment of AIDS can only be answered by ap- 
propriate clinical trials. In view of the magnitude of the 
AIDS pandemic, the absence of a protective vaccine, 
and the paucity of nontoxic therapy, the potential ap- 
plication of MAP 30 should be considered. 
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